Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
10.2337/db08-1193 140
RiskBenefit Assessment and Pharmacovigilance Needs Given the widespread use of GLP-1RAs and other incretin-based agents for obesity and T2D, comprehensive evaluation of even common GI adverse effects remains limited
"Dong-A ST's DPP4 inhibitor, SUGANON, got approved for type 2 diabetes in Korea"
In this context, Sample C exhibited the highest dispersibility value (92.74%), reflecting superior solubility performance
US$ 24.54
US$ 23.02
US$ 26.72
US$ 23.06
